LOS ANGELES, June 05, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Jefferies 2023 Global Healthcare Conference on Thursday, June 8, 2023 at 3:00 p.m. Eastern Time.
There will be simultaneous and archived webcasts available at https://wsw.com/webcast/jeff281/rdnt/1864720 and www.radnet.com under the "About RadNet'' menu section and "News and Press Releases'' sub-menu of the website.
| Details for RadNet's Presentation: | ||
| Date: | Thursday, June 8, 2023 | |
| Time: | 3:00 p.m. Eastern Time | |
| Location: | New York, NY | |
About RadNet, Inc.
RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 363 owned and/or operated outpatient imaging centers. RadNet's markets include California, Maryland, Delaware, New Jersey, New York, Florida and Arizona. In addition, RadNet provides radiology information technology and artificial intelligence solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 9,000 employees. For more information, visit http://www.radnet.com.
Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2928
| Last Trade: | US$72.25 |
| Daily Change: | -0.18 -0.25 |
| Daily Volume: | 405,798 |
| Market Cap: | US$5.350B |
January 08, 2025 December 04, 2024 December 02, 2024 December 02, 2024 December 01, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
